Cost-efficacy analysis of biological treatments in psoriasis: An 18-month assessment

Journal of Medical Economics

Volumn 8, Issue 139-146, 2005, Pages 139-146

  Menter, Alan ^a   Baker, Thomas ^b  

^a BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^b Zitter Group   (United States)

Author keywords

Alefacept; Biological agents; Cost efficacy; Efalizumab; Etanercept; Psoriasis

Indexed keywords

ALEFACEPT; EFALIZUMAB; ETANERCEPT; TOPICAL AGENT;

ANALYTICAL RESEARCH; CALCULATION; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DRUG ACTIVITY; DRUG APPROVAL; DRUG COST; DRUG DOSE REGIMEN; FEE; HEALTH CARE UTILIZATION; HUMAN; MAINTENANCE THERAPY; PATIENT MONITORING; PHOTOTHERAPY; PSORIASIS; QUALITY OF LIFE; REBOUND; RELATIVE BIOLOGIC EFFECTIVENESS; RESOURCE ALLOCATION; REVIEW; SENSITIVITY ANALYSIS; SIDE EFFECT; TREATMENT OUTCOME;

EID: 29944431973     PISSN: 1369698X     EISSN: None     Source Type: Journal    
DOI: 10.3111/200508135146     Document Type: Review

References (20)

1. Christophers E. Psoriasis: epidemiology and clinical spectrum. Clinical and Experimental Dermatology 2001; 26: 314-320.
2. National Psoriasis Foundation®. Benchmark survey on psoriasis and psoriatic arthritis: summary of top-line results. Available at: http://www.psoriasis.org/files/pdfs/press/npfsurvey.pdf. Accessed April 5,2005.
3. Callen JP, Krueger GG, Lebwohl M et al. AAD consensus Statement on psoriasis therapies. Journal of the American Academy of Dermatology 2003; 49: 897-899.
4. Sterry W, Barker J, Boehncke W-H et al. Biological therapies in the systemic management of psoriasis: International Consensus Conference. British Journal of Dermatology 2004; 151(Suppl. 69): 3-17.
5. Lebwohl M, Ali S. Treatment of psoriasis. Part 2. Systemic therapies. Journal of the American Academy of Dermatology 2001; 45: 649-661.
6. Koo J, Lebwohl M. Duration of remission of psoriasis therapies. Journal of the American Academy of Dermatology 1999; 41: 51-59.
7. McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Safety 2002; 25: 913-927.
8. Weinberg JM, Bottino CJ, Lindholm J et al. Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept. Journal of Drugs in Dermatology 2005; 4: 544-555.
9. Kipnis CD, Myers WA, Opeola M et al. Biologic treatments for psoriasis. Journal of the American Academy of Dermatology 2005; 52: 671-682.
10. Walley T. Why health economics matter. Journal of Dermatological Treatment 1999; 10(Suppl. 1): S3-7.
11. Chiou CF, Reyes E, Malone DC et al. Cost-efficacy comparison of biologies in the treatment of psoriasis. Presented at 62nd Annual Meeting of the American Academy of Dermatology; 2004 February 6-11; Washington, DC.
12. Abramovits W, Stevenson L. Comparison of biologic therapies for the treatment of psoriasis. Poster presented at 63rd Annual Meeting of the American Academy of Dermatology; 2005 February 18-22; New Orleans, LA.
13. Gordon KB, Langley RG. Remittive effects of intramuscular alefacept in psoriasis. Journal of the American Academy of Dermatology 2003; 2: 624-628.
14. Krueger GG, Papp KA, Stough DB et al., for the Alefacept Clinical Study Group. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. Journal of the American Academy of Dermatology 2002; 47: 821-833.
15. Average Wholesale Price, First DataBank, 2003.
16. The MEDSTAT Group, Inc. MEDSTAT DRG Guide. Ann Arbor, MI: Medstat, 2002.
17. National Heritage Insurance Company. 2003 Medicare Physician Fee Schedule (derived from the Medicare Resource-Based Relative Value Scale). Available at: http://www.medicarenhlc.com. Accessed April 5, 2005.
18. Gottlieb A, Gordon K, Caro I et al. Long-term efalizumab therapy safely maintains Psoriasis Area and Severity Index improvement: preliminary results from an open-label trial. Poster presented at 62nd Annual Meeting of the American Academy of Dermatology; 2004 February 6-11; Washington, DC.
19. Elewski B, Boh E, Papp K et al. Efficacy and safety of etanercept in patients with psoriasis: results of a global phase III study. Poster presented at 62nd Annual Meeting of the American Academy of Dermatology; 2004 February 6-11; Washington, DC.
20. Lebwohl M, Christophers E, Langley R et al., for the Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Archives of Dermatology 2003; 139: 719-727.